How serious a problem is bleeding in patients with acute coronary syndromes?
Review published in Current cardiology reports (2011)
Abstract
Recent studies have highlighted the critical importance of bleeding complications on prognosis in patients with acute coronary syndromes (ACS). In fact, the hazard for an adverse cardiovascular event associated with bleeding is similar to that of a myocardial infarction. Several bleeding risk scores are now available that reliably quantify the probability of an ACS patient experiencing a bleeding complication. Consistent and strong correlates of bleeding include older age, female sex, renal impairment, and an invasive management approach. Although patients who tend to bleed are usually more morbid compared with their non-bleeding counterparts, several lines of experimental and clinical evidence suggest an independent and causal pathway for bleeding-associated cardiovascular risk. Given the frequency and adverse prognosis associated with bleeding, interventions that might reduce such complications are now a major emphasis in the current era of ACS treatment. Recent trials have shown that several novel antithrombotics, bivalirudin and fondaparinux, reduce bleeding risk while maintaining efficacy in reducing ischemic events during ACS. Other promising strategies that continue to be tested include the use of vascular closure devices and transradial arterial access during percutaneous coronary intervention.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Recent studies have highlighted the critical importance of bleeding complications on prognosis in patients with acute coronary syndromes (ACS).
Por qué esto importa para la hirudoterapia
Este artículo de revisión examina la significación pronóstica de las complicaciones hemorrágicas en pacientes con síndromes coronarios agudos (SCA) y analiza las intervenciones que pueden reducir dichos riesgos. El resumen destaca que el sangrado se correlaciona con edad avanzada, sexo femenino, insuficiencia renal y manejo invasivo, e informa que ensayos recientes han demostrado que los nuevos antitrombóticos bivalirudina y fondaparinux reducen el riesgo hemorrágico mientras mantienen la eficacia en la reducción de eventos isquémicos durante el tratamiento del SCA. El resumen no menciona sanguijuelas, hirudoterapia, hirudina ni el secretoma de la sanguijuela, y no proporciona información sobre el origen o la derivación de la bivalirudina. Por lo tanto, este artículo no presenta una relevancia aparente para la American Society of Hirudotherapy basándose únicamente en su resumen.
Citación
How serious a problem is bleeding in patients with acute coronary syndromes?
Baber U et al. · Current cardiology reports, 2011
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026